The DOI matches its Crossref record; 125 of the 125 references it cites were found in a registry or an index.
Treatment of muscle‐invasive and advanced bladder cancer in 2020
Open accessAbstract
Bladder cancer accounts for nearly 170,000 deaths worldwide annually. For over 4 decades, the systemic management of muscle‐invasive and advanced bladder cancer has primarily consisted of platinum‐based chemotherapy. Over the past 10 years, innovations in sequencing technologies have led to rapid genomic characterization of bladder cancer, deepening our understanding of bladder cancer pathogenesis and exposing potential therapeutic vulnerabilities. On the basis of its high mutational burden, immune checkpoint inhibitors were investigated in advanced bladder cancer, revealing durable responses in a subset of patients. These agents are now approved for several indications and highlight the changing treatment landscape of advanced bladder cancer. In addition, commonly expressed molecular targets were leveraged to develop targeted therapies, such as fibroblast growth factor receptor inhibitors and antibody‐drug conjugates. The molecular characterization of bladder cancer and the development of novel therapies also have stimulated investigations into optimizing treatment approaches for muscle‐invasive bladder cancer. Herein, the authors review the history of muscle‐invasive and advanced bladder cancer management, highlight the important molecular characteristics of bladder cancer, describe the major advances in treatment, and offer future directions for therapeutic development.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bray, F., Ferlay, J., Soerjomataram, I., Siegel, R. L., Torre, L. A., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21492 · Cited by 84,109
Jemal, A., Bray, F., Center, M. M., Ferlay, J., Ward, E., & Forman, D. (2011) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20107 · Cited by 54,679
Global cancer statistics, 2012
Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet‐Tieulent, J., & Jemal, A. (2015) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21262 · Cited by 26,850
Siegel, R. L., Miller, K. D., & Jemal, A. (2018) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21442 · Cited by 16,579
Pembrolizumab plus chemotherapy in metastatic non–small-cell lung cancer
Gandhi, L., Rodríguez-Abreu, D., Gadgeel, S., Esteban, E., Felip, E., De Angelis, F., Domine, M., Clingan, P., Hochmair, M. J., Powell, S. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801005 · Cited by 6,607
Nivolumab plus Ipilimumab versus Sunitinib in Advanced Renal-Cell Carcinoma
Motzer, R. J., Tannir, N. M., McDermott, D. F., Arén Frontera, O., Melichar, B., Choueiri, T. K., Plimack, E. R., Barthélémy, P., Porta, C., George, S., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712126 · Cited by 4,656
Rosenberg, J. E., Hoffman-Censits, J., Powles, T., van der Heijden, M. S., Balar, A. V., Necchi, A., Dawson, N., O'Donnell, P. H., Balmanoukian, A., Loriot, Y., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00561-4 · Cited by 3,669
Self-citationRadical Cystectomy in the Treatment of Invasive Bladder Cancer: Long-Term Results in 1,054 Patients
Stein, J. P., Lieskovsky, G., Cote, R., Groshen, S., Feng, A.-C., Boyd, S., Skinner, E., Bochner, B., Thangathurai, D., Mikhail, M., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.3.666 · Cited by 3,530
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Comprehensive molecular characterization of urothelial bladder carcinoma
Perou, C. M. (2019) · Carolina Digital Repository (University of North Carolina at Chapel Hill) · doi:10.17615/za09-dk57 · Cited by 2,990
Nivolumab plus ipilimumab in advanced non-small-cell lung cancer
Hellmann, M. D., Paz-Ares, L., Bernabe Caro, R., Zurawski, B., Kim, S.-W., Carcereny Costa, E., Park, K., Alexandru, A., Lupinacci, L., de la Mora Jimenez, E., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910231 · Cited by 2,823
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma
Postow, M. A., Chesney, J., Pavlick, A. C., Robert, C., Grossmann, K., McDermott, D., Linette, G. P., Meyer, N., Giguere, J. K., Agarwala, S. S., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1414428 · Cited by 2,781
Fibroblast growth factor signalling: from development to cancer
Turner, N., & Grose, R. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2780 · Cited by 2,693
Grossman, H. B., Natale, R. B., Tangen, C. M., Speights, V. O., Vogelzang, N. J., Trump, D. L., White, R. W. D., Sarosdy, M. F., Wood, D. P., Raghavan, D., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa022148 · Cited by 2,668
Comprehensive Molecular Characterization of Muscle-Invasive Bladder Cancer
Robertson, A. G., Kim, J., Al-Ahmadie, H., Bellmunt, J., Guo, G., Cherniack, A. D., Hinoue, T., Laird, P. W., Hoadley, K. A., Akbani, R., et al. (2017) · Cell · doi:10.1016/j.cell.2017.09.007 · Cited by 2,443
von der Maase, H., Hansen, S. W., Roberts, J. T., Dogliotti, L., Oliver, T., Moore, M. J., Bodrogi, I., Albers, P., Knuth, A., Lippert, C. M., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3068 · Cited by 2,279
Balar, A. V., Galsky, M. D., Rosenberg, J. E., Powles, T., Petrylak, D. P., Bellmunt, J., Loriot, Y., Necchi, A., Hoffman-Censits, J., Perez-Gracia, J. L., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32455-2 · Cited by 2,199
Self-citationPolychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Curran, M. A., Montalvo, W., Yagita, H., & Allison, J. P. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0915174107 · Cited by 1,874
von der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., Moore, M. J., Zimmermann, A., & Arning, M. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.07.757 · Cited by 1,850
Sharma, P., Retz, M., Siefker-Radtke, A., Baron, A., Necchi, A., Bedke, J., Plimack, E. R., Vaena, D., Grimm, M.-O., Bracarda, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30065-7 · Cited by 1,736
Self-citationChoi, W., Porten, S., Kim, S., Willis, D., Plimack, E. R., Hoffman-Censits, J., Roth, B., Cheng, T., Tran, M., Lee, I.-L., et al. (2014) · Cancer Cell · doi:10.1016/j.ccr.2014.01.009 · Cited by 1,716
Kamat, A. M., Hahn, N. M., Efstathiou, J. A., Lerner, S. P., Malmström, P.-U., Choi, W., Guo, C. C., Lotan, Y., & Kassouf, W. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30512-8 · Cited by 1,421
Powles, T., Durán, I., van der Heijden, M. S., Loriot, Y., Vogelzang, N. J., De Giorgi, U., Oudard, S., Retz, M. M., Castellano, D., Bamias, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33297-x · Cited by 1,408
Balar, A. V., Castellano, D., O'Donnell, P. H., Grivas, P., Vuky, J., Powles, T., Plimack, E. R., Hahn, N. M., de Wit, R., Pang, L., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30616-2 · Cited by 1,333
American Joint Committee on Cancer (2010) · Springer eBooks · doi:10.1007/978-0-387-88441-7 · Cited by 1,328
Vale, C. L. (2005) · European Urology · doi:10.1016/j.eururo.2005.04.006 · Cited by 1,325
Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity
Knowles, M. A., & Hurst, C. D. (2015) · Nature Reviews Cancer · doi:10.1038/nrc3817 · Cited by 1,247
Gill, S., Loprinzi, C. L., Sargent, D. J., Thomé, S. D., Alberts, S. R., Haller, D. G., Benedetti, J., Francini, G., Shepherd, L. E., Francois Seitz, J., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.09.059 · Cited by 1,021
Loehrer, P. J., Einhorn, L. H., Elson, P. J., Crawford, E. D., Kuebler, P., Tannock, I., Raghavan, D., Stuart-Harris, R., Sarosdy, M. F., & Lowe, B. A. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.7.1066 · Cited by 981
Radiotherapy with or without Chemotherapy in Muscle-Invasive Bladder Cancer
James, N. D., Hussain, S. A., Hall, E., Jenkins, P., Tremlett, J., Rawlings, C., Crundwell, M., Sizer, B., Sreenivasan, T., Hendron, C., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1106106 · Cited by 962
International Collaboration of Trialists on behalf of the Medical Research Council Advanced Bladder Cancer Working Party (now the National Cancer Research Institute Bladder Cancer Clinical Studies Group), T. E. O. F. R. A. T. O. C. G.-U. T. C. G. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.3139 · Cited by 949
A Molecular Taxonomy for Urothelial Carcinoma
Sjödahl, G., Lauss, M., Lövgren, K., Chebil, G., Gudjonsson, S., Veerla, S., Patschan, O., Aine, M., Fernö, M., Ringnér, M., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-0077-t · Cited by 944
Intrinsic subtypes of high-grade bladder cancer reflect the hallmarks of breast cancer biology
Damrauer, J. S., Hoadley, K. A., Chism, D. D., Fan, C., Tiganelli, C. J., Wobker, S. E., Yeh, J. J., Milowsky, M. I., Iyer, G., Parker, J. S., et al. (2014) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1318376111 · Cited by 877
Zitvogel, L., Galluzzi, L., Smyth, M. J., & Kroemer, G. (2013) · Immunity · doi:10.1016/j.immuni.2013.06.014 · Cited by 870
Powles, T., O'Donnell, P. H., Massard, C., Arkenau, H.-T., Friedlander, T. W., Hoimes, C. J., Lee, J. L., Ong, M., Sridhar, S. S., Vogelzang, N. J., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2017.2411 · Cited by 869
Massard, C., Gordon, M. S., Sharma, S., Rafii, S., Wainberg, Z. A., Luke, J., Curiel, T. J., Colon-Otero, G., Hamid, O., Sanborn, R. E., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.9761 · Cited by 840
Seiler, R., Ashab, H. A. D., Erho, N., van Rhijn, B. W. G., Winters, B., Douglas, J., Van Kessel, K. E., Fransen van de Putte, E. E., Sommerlad, M., Wang, N. Q., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.03.030 · Cited by 786
Galsky, M. D., Arija, J. Á. A., Bamias, A., Davis, I. D., De Santis, M., Kikuchi, E., Garcia-del-Muro, X., De Giorgi, U., Mencinger, M., Izumi, K., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)30230-0 · Cited by 786
Self-citationDe Santis, M., Bellmunt, J., Mead, G., Kerst, J. M., Leahy, M., Maroto, P., Gil, T., Marreaud, S., Daugaard, G., Skoneczna, I., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.37.3571 · Cited by 778
Bellmunt, J., Théodore, C., Demkov, T., Komyakov, B., Sengelov, L., Daugaard, G., Caty, A., Carles, J., Jagiello-Gruszfeld, A., Karyakin, O., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.20.5534 · Cited by 766
Necchi, A., Anichini, A., Raggi, D., Briganti, A., Massa, S., Lucianò, R., Colecchia, M., Giannatempo, P., Mortarini, R., Bianchi, M., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.01148 · Cited by 741
Sharma, P., Callahan, M. K., Bono, P., Kim, J., Spiliopoulou, P., Calvo, E., Pillai, R. N., Ott, P. A., de Braud, F., Morse, M., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30496-x · Cited by 678
Sternberg, C. N., Yagoda, A., Scher, H. I., Watson, R. C., Ahmed, T., Weiselberg, L. R., Geller, N., Hollander, P. S., Herr, H. W., Sogani, P. C., et al. (1985) · Journal of Urology · doi:10.1016/s0022-5347(17)48996-8 · Cited by 654
Sternberg, C. N., de Mulder, P. H. M., Schornagel, J. H., Théodore, C., Fossa, S. D., van Oosterom, A. T., Witjes, F., Spina, M., van Groeningen, C. J., de Balincourt, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.10.2638 · Cited by 628
Somatic ERCC2 Mutations Correlate with Cisplatin Sensitivity in Muscle-Invasive Urothelial Carcinoma
Van Allen, E. M., Mouw, K. W., Kim, P., Iyer, G., Wagle, N., Al-Ahmadie, H., Zhu, C., Ostrovnaya, I., Kryukov, G. V., O'Connor, K. W., et al. (2014) · Cancer Discovery · doi:10.1158/2159-8290.cd-14-0623 · Cited by 620
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
Bouwman, P., & Jonkers, J. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3342 · Cited by 615
Powles, T., Kockx, M., Rodriguez-Vida, A., Duran, I., Crabb, S. J., Van Der Heijden, M. S., Szabados, B., Pous, A. F., Gravis, G., Herranz, U. A., et al. (2019) · Nature Medicine · doi:10.1038/s41591-019-0628-7 · Cited by 591
Patel, M. R., Ellerton, J., Infante, J. R., Agrawal, M., Gordon, M., Aljumaily, R., Britten, C. D., Dirix, L., Lee, K.-W., Taylor, M., et al. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30900-2 · Cited by 590
Apolo, A. B., Infante, J. R., Balmanoukian, A., Patel, M. R., Wang, D., Kelly, K., Mega, A. E., Britten, C. D., Ravaud, A., Mita, A. C., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.71.6795 · Cited by 585
Sternberg, C. N., de Mulder, P., Schornagel, J. H., Theodore, C., Fossa, S. D., van Oosterom, A. T., Witjes, J. A., Spina, M., van Groeningen, C. J., Duclos, B., et al. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2005.08.032 · Cited by 542
Sharma, P., Shen, Y., Wen, S., Yamada, S., Jungbluth, A. A., Gnjatic, S., Bajorin, D. F., Reuter, V. E., Herr, H., Old, L. J., et al. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0611618104 · Cited by 526
Bellmunt, J., von der Maase, H., Mead, G. M., Skoneczna, I., De Santis, M., Daugaard, G., Boehle, A., Chevreau, C., Paz-Ares, L., Laufman, L. R., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.38.6979 · Cited by 526
Plimack, E. R., Dunbrack, R. L., Brennan, T. A., Andrake, M. D., Zhou, Y., Serebriiskii, I. G., Slifker, M., Alpaugh, K., Dulaimi, E., Palma, N., et al. (2015) · European Urology · doi:10.1016/j.eururo.2015.07.009 · Cited by 519
Mak, R. H., Hunt, D., Shipley, W. U., Efstathiou, J. A., Tester, W. J., Hagan, M. P., Kaufman, D. S., Heney, N. M., & Zietman, A. L. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.57.5548 · Cited by 465
Cumberbatch, M. G., Rota, M., Catto, J. W. F., & La Vecchia, C. (2016) · European Urology · doi:10.1016/j.eururo.2015.06.042 · Cited by 451
Dash, A., Galsky, M. D., Vickers, A. J., Serio, A. M., Koppie, T. M., Dalbagni, G., & Bochner, B. H. (2006) · Cancer · doi:10.1002/cncr.22031 · Cited by 435
Self-citationCYSTECTOMY FOR BLADDER CANCER: A CONTEMPORARY SERIES
DALBAGNI, G., GENEGA, E., HASHIBE, M., ZHANG, Z.-F., RUSSO, P., HERR, H., & REUTER, V. (2001) · Journal of Urology · doi:10.1016/s0022-5347(05)66440-3 · Cited by 434
Nogova, L., Sequist, L. V., Perez Garcia, J. M., Andre, F., Delord, J.-P., Hidalgo, M., Schellens, J. H. M., Cassier, P. A., Camidge, D. R., Schuler, M., et al. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.2048 · Cited by 432
Sternberg, C. N., Skoneczna, I., Kerst, J. M., Albers, P., Fossa, S. D., Agerbaek, M., Dumez, H., de Santis, M., Théodore, C., Leahy, M. G., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(14)71160-x · Cited by 389
Wang, Y., Deng, W., Li, N., Neri, S., Sharma, A., Jiang, W., & Lin, S. H. (2018) · Frontiers in Pharmacology · doi:10.3389/fphar.2018.00185 · Cited by 374
Galsky, M. D., Hahn, N. M., Rosenberg, J., Sonpavde, G., Hutson, T., Oh, W. K., Dreicer, R., Vogelzang, N., Sternberg, C., Bajorin, D. F., et al. (2011) · The Lancet Oncology · doi:10.1016/s1470-2045(10)70275-8 · Cited by 356
Self-citationPloussard, G., Daneshmand, S., Efstathiou, J. A., Herr, H. W., James, N. D., Rödel, C. M., Shariat, S. F., Shipley, W. U., Sternberg, C. N., Thalmann, G. N., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.02.038 · Cited by 355
Dadhania, V., Zhang, M., Zhang, L., Bondaruk, J., Majewski, T., Siefker-Radtke, A., Guo, C. C., Dinney, C., Cogdell, D. E., Zhang, S., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.08.036 · Cited by 345
Dogliotti, L., Cartenì, G., Siena, S., Bertetto, O., Martoni, A., Bono, A., Amadori, D., Onat, H., & Marini, L. (2007) · European Urology · doi:10.1016/j.eururo.2006.12.029 · Cited by 330
Prevalence and Co-Occurrence of Actionable Genomic Alterations in High-Grade Bladder Cancer
Iyer, G., Al-Ahmadie, H., Schultz, N., Hanrahan, A. J., Ostrovnaya, I., Balar, A. V., Kim, P. H., Lin, O., Weinhold, N., Sander, C., et al. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2012.46.5740 · Cited by 309
Multicenter Assessment of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer
Zargar, H., Espiritu, P. N., Fairey, A. S., Mertens, L. S., Dinney, C. P., Mir, M. C., Krabbe, L.-M., Cookson, M. S., Jacobsen, N.-E., Gandhi, N. M., et al. (2015) · European Urology · doi:10.1016/j.eururo.2014.09.007 · Cited by 294
Dinney, C. P. N., McConkey, D. J., Millikan, R. E., Wu, X., Bar-Eli, M., Adam, L., Kamat, A. M., Siefker-Radtke, A. O., Tuziak, T., Sabichi, A. L., et al. (2004) · Cancer Cell · doi:10.1016/j.ccr.2004.08.002 · Cited by 290
Plimack, E. R., Hoffman-Censits, J. H., Viterbo, R., Trabulsi, E. J., Ross, E. A., Greenberg, R. E., Chen, D. Y. T., Lallas, C. D., Wong, Y.-N., Lin, J., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.53.2465 · Cited by 287
Use of Radical Cystectomy for Patients With Invasive Bladder Cancer
Gore, J. L., Litwin, M. S., Lai, J., Yano, E. M., Madison, R., Setodji, C., Adams, J. L., Saigal, C. S., & the Urologic Diseases in America Project (2010) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djq121 · Cited by 278
Yasuda, S., Sho, M., Yamato, I., Yoshiji, H., Wakatsuki, K., Nishiwada, S., Yagita, H., & Nakajima, Y. (2013) · Clinical and Experimental Immunology · doi:10.1111/cei.12069 · Cited by 276
Dirkx, A. E. M., Egbrink, M. G. A. O., Castermans, K., van der Schaft, D. W. J., Thijssen, V. L. J. L., Dings, R. P. M., Kwee, L., Mayo, K. H., Wagstaff, J., Steege, J. C. A. B., et al. (2006) · The FASEB Journal · doi:10.1096/fj.05-4493com · Cited by 270
Pathologic complete response to neoadjuvant cisplatin in BRCA1-positive breast cancer patients
Byrski, T., Huzarski, T., Dent, R., Marczyk, E., Jasiowka, M., Gronwald, J., Jakubowicz, J., Cybulski, C., Wisniowski, R., Godlewski, D., et al. (2014) · Breast Cancer Research and Treatment · doi:10.1007/s10549-014-3100-x · Cited by 269
Three differentiation states risk-stratify bladder cancer into distinct subtypes
Volkmer, J.-P., Sahoo, D., Chin, R. K., Ho, P. L., Tang, C., Kurtova, A. V., Willingham, S. B., Pazhanisamy, S. K., Contreras-Trujillo, H., Storm, T. A., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1120605109 · Cited by 259
Liu, D., Plimack, E. R., Hoffman-Censits, J., Garraway, L. A., Bellmunt, J., Van Allen, E., & Rosenberg, J. E. (2016) · JAMA Oncology · doi:10.1001/jamaoncol.2016.1056 · Cited by 259
Pal, S. K., Rosenberg, J. E., Hoffman-Censits, J. H., Berger, R., Quinn, D. I., Galsky, M. D., Wolf, J., Dittrich, C., Keam, B., Delord, J.-P., et al. (2018) · Cancer Discovery · doi:10.1158/2159-8290.cd-18-0229 · Cited by 258
Self-citationPhase II Trial of Gemcitabine Plus Cisplatin in Patients With Metastatic Urothelial Cancer
Kaufman, D., Raghavan, D., Carducci, M., Levine, E. G., Murphy, B., Aisner, J., Kuzel, T., Nicol, S., Oh, W., & Stadler, W. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.9.1921 · Cited by 257
Self-citationOccupation and bladder cancer among men in Western Europe
Kogevinas, M., Mannetje, A. '., Cordier, S., Ranft, U., González, C. A., Vineis, P., Chang-Claude, J., Lynge, E., Wahrendorf, J., Tzonou, A., et al. (2003) · Cancer Causes & Control · doi:10.1023/b:caco.0000007962.19066.9c · Cited by 254
Donat, S. M., Shabsigh, A., Savage, C., Cronin, A. M., Bochner, B. H., Dalbagni, G., Herr, H. W., & Milowsky, M. I. (2009) · European Urology · doi:10.1016/j.eururo.2008.07.018 · Cited by 252
Sharma, P., Siefker-Radtke, A., de Braud, F., Basso, U., Calvo, E., Bono, P., Morse, M. A., Ascierto, P. A., Lopez-Martin, J., Brossart, P., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.19.00538 · Cited by 243
Anti-VEGF therapies in the clinic
Meadows, K. L., & Hurwitz, H. I. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006577 · Cited by 237
Bellmunt, J., Ribas, A., Eres, N., Albanell, J., Almanza, C., Bermejo, B., Sol�, L.-A., & Baselga, J. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19971115)80:10<1966::aid-cncr14>3.0.co;2-w · Cited by 228
Stadler, W. M., Lerner, S. P., Groshen, S., Stein, J. P., Shi, S.-R., Raghavan, D., Esrig, D., Steinberg, G., Wood, D., Klotz, L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.34.4028 · Cited by 224
Groenendijk, F. H., de Jong, J., Fransen van de Putte, E. E., Michaut, M., Schlicker, A., Peters, D., Velds, A., Nieuwland, M., van den Heuvel, M. M., Kerkhoven, R. M., et al. (2016) · European Urology · doi:10.1016/j.eururo.2015.01.014 · Cited by 223
Cognetti, F., Ruggeri, E. M., Felici, A., Gallucci, M., Muto, G., Pollera, C. F., Massidda, B., Rubagotti, A., Giannarelli, D., Boccardo, F., et al. (2012) · Annals of Oncology · doi:10.1093/annonc/mdr354 · Cited by 222
Droller, M. J. (2000) · PubMed · Cited by 207
Yafi, F. A., Aprikian, A. G., Chin, J. L., Fradet, Y., Izawa, J., Estey, E., Fairey, A., Rendon, R., Cagiannos, I., Lacombe, L., et al. (2011) · BJU International · doi:10.1111/j.1464-410x.2010.09912.x · Cited by 206
Sonpavde, G., Goldman, B. H., Speights, V. O., Lerner, S. P., Wood, D. P., Vogelzang, N. J., Trump, D. L., Natale, R. B., Grossman, H. B., & Crawford, E. D. (2009) · Cancer · doi:10.1002/cncr.24466 · Cited by 195
Effectiveness of Adjuvant Chemotherapy for Locally Advanced Bladder Cancer
Galsky, M. D., Stensland, K. D., Moshier, E., Sfakianos, J. P., McBride, R. B., Tsao, C.-K., Casey, M., Boffetta, P., Oh, W. K., Mazumdar, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.64.1076 · Cited by 192
Self-citationMagers, M. J., Lopez‐Beltran, A., Montironi, R., Williamson, S. R., Kaimakliotis, H. Z., & Cheng, L. (2019) · Histopathology · doi:10.1111/his.13734 · Cited by 190
Papafotiou, G., Paraskevopoulou, V., Vasilaki, E., Kanaki, Z., Paschalidis, N., & Klinakis, A. (2016) · Nature Communications · doi:10.1038/ncomms11914 · Cited by 172
Huddart, R. A., Birtle, A., Maynard, L., Beresford, M., Blazeby, J., Donovan, J., Kelly, J. D., Kirkbank, T., McLaren, D. B., Mead, G., et al. (2017) · BJU International · doi:10.1111/bju.13900 · Cited by 172
Petrylak, D. P., de Wit, R., Chi, K. N., Drakaki, A., Sternberg, C. N., Nishiyama, H., Castellano, D., Hussain, S., Fléchon, A., Bamias, A., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)32365-6 · Cited by 171
von der Maase, H., Sengelov, L., Roberts, J. T., Ricci, S., Dogliotti, L., Oliver, T., Moore, M. J., Zimmermann, A., & Arning, M. (2006) · Journal of Urology · doi:10.1016/s0022-5347(05)00370-8 · Cited by 169
Quality of Life in Long-term Survivors of Muscle-Invasive Bladder Cancer
Mak, K. S., Smith, A. B., Eidelman, A., Clayman, R., Niemierko, A., Cheng, J.-S., Matthews, J., Drumm, M. R., Nielsen, M. E., Feldman, A. S., et al. (2016) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2016.08.023 · Cited by 165
Petrioli, R., Frediani, B., Manganelli, A., Barbanti, G., De Capua, B., De Lauretis, A., Salvestrini, F., Mondillo, S., & Francini, G. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960115)77:2<344::aid-cncr18>3.0.co;2-1 · Cited by 164
Warrick, J. I., Walter, V., Yamashita, H., Chung, E., Shuman, L., Amponsa, V. O., Zheng, Z., Chan, W. H.-C., Whitcomb, T. L., Yue, F., et al. (2016) · Scientific Reports · doi:10.1038/srep38531 · Cited by 150
Coen, J. J., Zhang, P., Saylor, P. J., Lee, C. T., Wu, C., Parker, W., Lautenschlaeger, T., Zietman, A. L., Efstathiou, J. A., Jani, A. B., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.18.00537 · Cited by 150
Necchi, A., Mariani, L., Zaffaroni, N., Schwartz, L. H., Giannatempo, P., Crippa, F., Morosi, C., Lanocita, R., Sava, T., Ortega, C., et al. (2012) · The Lancet Oncology · doi:10.1016/s1470-2045(12)70294-2 · Cited by 140
Iyer, G., Balar, A. V., Milowsky, M. I., Bochner, B. H., Dalbagni, G. M., Donat, S. M., Herr, H. W., Huang, W. C. W., Taneja, S. S., Woods, M. E., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.75.0158 · Cited by 140
Phase 2 trial of sorafenib in patients with advanced urothelial cancer
Dreicer, R., Li, H., Stein, M. N., DiPaola, R. S., Eleff, M. K., Roth, B. J., & Wilding, G. (2009) · Cancer · doi:10.1002/cncr.24467 · Cited by 138
Splinter, T. A. W., Scher, H. I., Denis, L., Bukowski, R., Simon, S., Klimberg, I. W., Soloway, M. S., Vogelzang, N. J., van Tinteren, H., & Herr, H. W. (1992) · The Journal of Urology · doi:10.1016/s0022-5347(17)37318-4 · Cited by 128
Joaquim Bellmunt, B., González-Larriba, J. L., Prior, C., Maroto, P., Carles, J., Castellano, D., Mellado, B., Gallardo, E., Perez‐Gracia, J. L., Aguilar, G., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr023 · Cited by 127
Arcangeli, G., Strigari, L., & Arcangeli, S. (2015) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2015.04.006 · Cited by 122
Galsky, M. D., Wang, H., Hahn, N. M., Twardowski, P. W., Pal, S. K., Albany, C., Fleming, M. T., Starodub, A., Hauke, R. J., Yu, M., et al. (2017) · European Urology · doi:10.1016/j.eururo.2017.12.001 · Cited by 119
Self-citationMilowsky, M. I., Dittrich, C., Durán, I., Jagdev, S., Millard, F. E., Sweeney, C. J., Bajorin, D. F., Cerbone, L., Quinn, D. I., Stadler, W. M., et al. (2014) · European Journal of Cancer · doi:10.1016/j.ejca.2014.10.013 · Cited by 118
Molecular Mechanisms and Pathways in Bladder Cancer Development and Progression
Jung, I., & Messing, E. M. (2000) · Cancer Control · doi:10.1177/107327480000700401 · Cited by 109
Soukup, V., Čapoun, O., Cohen, D. L., Hernández, V., Burger, M., Compérat, É., Gontero, P., Lam, T. B. L., Mostafid, H. A., Palou, J., et al. (2018) · European Urology Focus · doi:10.1016/j.euf.2018.11.005 · Cited by 107
Cahn, D. B., Handorf, E. A., Ghiraldi, E. M., Ristau, B. T., Geynisman, D. M., Churilla, T. M., Horwitz, E. M., Sobczak, M. L., Chen, D. Y. T., Viterbo, R., et al. (2017) · Cancer · doi:10.1002/cncr.30900 · Cited by 106
Socinski, M. A., Jotte, R. M., Cappuzzo, F., Orlandi, F., Stroyakovskiy, D., Nogami, N., Rodríguez‐Abreu, D., Moro‐Sibilot, D., Thomas, C. A., Barlési, F., et al. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2018.36.15_suppl.9002 · Cited by 88
Tagawa, S. T., Faltas, B. M., Lam, E. T., Saylor, P. J., Bardia, A., Hajdenberg, J. J., Morgans, A. K., Lim, E. A., Kalinsky, K. M., Simpson, P. S., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.7_suppl.354 · Cited by 84
Self-citationSridhar, S. S., Winquist, E., Eisen, A. F., Hotte, S. J., McWhirter, E., Tannock, I. F., Mukherjee, S. D., Wang, L. E., Blattler, C., Wright, J. J., et al. (2010) · Investigational New Drugs · doi:10.1007/s10637-010-9408-4 · Cited by 79
Selby, M., Engelhardt, J., Lü, L., Quigley, M. M., Wang, C., Chen, B., & Korman, A. J. (2013) · Journal of Clinical Oncology · doi:10.1200/jco.2013.31.15_suppl.3061 · Cited by 75
Morrison, K., Challita-Eid, P. M., An, Z., Yang, P., Yang, P., Abad, J. D., Liu, W., Lortie, D. R., Snyder, J., Capo, L., et al. (2016) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-15-0570 · Cited by 71
Cappuzzo, F., McCleod, M., Hussein, M., Morabito, A., Rittmeyer, A., Conter, H. J., Kopp, H.-G., Daniel, D., McCune, S., Mekhail, T., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy424.065 · Cited by 57
Santis, M. D., Wiechno, P., Joaquim Bellmunt, B., Lucas, C., Su, W., Albiges, L. K., Lin, C.-C., Senkus, E., Fléchon, A., Mourey, L., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv609 · Cited by 55
Targeting the VEGF pathway in metastatic bladder cancer
Mazzola, C. R., & Chin, J. L. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1041588 · Cited by 51
The Role of Neoadjuvant Trials in Drug Development for Solid Tumors
Funt, S. A., & Chapman, P. B. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-1961 · Cited by 48
Chemoprevention of bladder cancer
Golijanin, D. J., Kakiashvili, D., Madeb, R. R., Messing, E. M., & Lerner, S. P. (2006) · World Journal of Urology · doi:10.1007/s00345-006-0123-x · Cited by 31
Holmsten, K., Jensen, N. V., Mouritsen, L. S., Jonsson, E., Mellnert, C., Agerbæk, M., Nilsson, C., Moe, M., Carus, A., Öfverholm, E., et al. (2019) · European Journal of Cancer · doi:10.1016/j.ejca.2019.08.033 · Cited by 27
Gallagher, D. J., Al‐Ahmadie, H. A., Ostrovnaya, I., Gerst, S. R., Regazzi, A. M., Garcia-Grossman, I. R., Riches, J. C., Gounder, S., Flaherty, A.-M., Trout, A., et al. (2011) · European Urology · doi:10.1016/j.eururo.2011.05.034 · Cited by 26
Yasuda, S., Sho, M., Yamato, I., Yoshiji, H., Wakatsuki, K., Nishiwada, S., Yagita∥, H., & Nakajima, Y. (2013) · Institutional Repositories DataBase (IRDB) · Cited by 23
van der Heijden, M. S., van Dijk, N., Smit, L. A., Hendricksen, K., de Feijter, J. M., Bekers, E. M., Hooijberg, E., van Rooijen, C. C. N., Broeks, A., Lubeck, Y., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz249.003 · Cited by 20
Abstract CT112: Durvalumab + tremelimumab in patients with metastatic urothelial cancer
Balar, A. V., Mahipal, A., Grande, E., et al. (2018) · Cancer Research · doi:10.1158/1538-7445.am2018-ct112 · Cited by 15
Cited by
Iron Homeostasis and Ferroptosis in Human Diseases: Mechanisms and Therapeutic Prospects
Ru, Q., Li, Y., Chen, L., Wu, Y., Min, J., & Wang, F. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01969-z · Cited by 724
Emerging new therapeutic antibody derivatives for cancer treatment
Jin, S., Sun, Y., Liang, X., Gu, X., Ning, J., Xu, Y., Chen, S., & Pan, L. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-021-00868-x · Cited by 459
Sheng, X., Yan, X., Wang, L., Shi, Y., Yao, X., Luo, H., Shi, B., Liu, J., He, Z., Yu, G., et al. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-2488 · Cited by 284
Li, H., Chen, J., Li, Z., Chen, M., Ou, Z., Mo, M., Wang, R., Tong, S., Liu, P., Cai, Z., et al. (2023) · Advanced Science · doi:10.1002/advs.202300110 · Cited by 49
Pederzoli, F., Riba, M., Venegoni, C., Marandino, L., Bandini, M., Alchera, E., Locatelli, I., Raggi, D., Giannatempo, P., Provero, P., et al. (2024) · European Urology · doi:10.1016/j.eururo.2023.12.014 · Cited by 33
Metadata
- Authors
- Patel, V. G., Oh, W. K., & Galsky, M. D.
- Venue
- CA: A Cancer Journal for Clinicians
- Publisher
- Wiley
- Published
- 2020-08-07
- Volume
- 70
- Issue
- 5
- Pages
- 404-423
- ISSN
- 0007-9235 (ISSN-L)
- 1542-4863
- OpenAlex
- W3048201207
- Cited by
- 1,014
- References
- 125
- FWCI
- 114.39
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.